开启辅助访问      

聚彩彩票家园

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索

美国制药商开始进行新冠肺炎抗体试验最后阶段

发布者: 千缘 | 发布时间: 2020-7-31 02:25| 查看数: 113| 评论数: 0|



US Drugmaker Begins Late Stage COVID-19 Antibodies Trial

美国制药商开始进行新冠肺炎抗体试验最后阶段

From VOA Learning English, this is the Health and Lifestyle report.

这里是VOA慢速聚彩彩票健康生活报道。

Drug-maker Regeneron Pharmaceuticals announced on Monday it has started late stage human testing of an antibody treatment for COVID-19. It said the tests are designed to show the drug's effectiveness in preventing and treating the disease.

美国再生元制药公司周一宣布,其已开始进行新冠肺炎抗体治疗药物试验的最后阶段——人体试验。该公司表示,试验旨在证明这种药物在预防和治疗新冠肺炎方面的有效性。

Regeneron is launching one of the drug trials jointly with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The company said the goal is to test the drug's ability to prevent infections in persons who have had close contact with a COVID-19 patient.

再生元公司正在与美国国家过敏症和传染病研究所(简称NIAID)联合开展其中一项药物试验。该公司表示,其目标是测试这种药物在新冠肺炎患者密切接触人群中预防感染的能力。

Regeneron said it hopes the late-stage drug trial will involve about 2,000 patients across the United States.

再生元公司表示,其希望约2000名美国患者参与药物试验的最后阶段。

George D. Yancopoulos is a co-founder and president of the New York-based company. He said in a statement, "We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, evenin the midst ofan ongoing global pandemic."

乔治·D·扬科普洛斯是总部位于纽约的再生元公司的联合创始人兼总裁。他在声明中表示,“聚彩彩票同步开展适应性试验,以便尽快采取行动,为预防和治疗新冠肺炎感染提供潜在的解决方案,即使是在全球大流行的情况下?!?br />
Yancopoulos noted that the antibody treatment "could be available much sooner than a vaccine."

扬科普洛斯指出,抗体治疗“投入使用的时间可能远远早于疫苗”。

Regeneron is holding two separate late stage trials following a positive review from an independent group of REGN-COV2 Phase 1 safety results. The earlier tests involved 30 hospitalized and non-hospitalized patients with COVID-19.

再生元公司正在进行两个独立的最后阶段试验,此前该公司从一个独立组织得到了REGN-COV2第一阶段安全性结果的正面评测。30名新冠肺炎住院患者和非住院患者参与了早期试验。

The company said the late-stage Phase 3 prevention trial willtake placeat about 100 testing centers in the U.S. The aim of the trial is to examine SARS-CoV-2 infection status. SARS-CoV-2 is the virus that cause COVID-19 disease.

该公司表示,第三阶段,也就是最后阶段的预防试验将在美国约100个检测中心进行。试验目的是检查SARS-CoV-2病毒的感染状况。SARS-CoV-2是引发新冠肺炎的病毒。

The other Phase 2 and 3 treatment trials are planned across 150 sites in the U.S., Brazil, Mexico and Chile. The trials will include over 1,800 hospitalized and 1,000 non-hospitalized patients.

另一个第二阶段和第二阶段治疗试验计划在美国、巴西、墨西哥和智利的150个地点进行。这些试验将涵盖超过1800名住院患者和1000名非住院患者。

Antibodies are chemical molecules. The body's natural defenses produce antibodies tofight offinfection.

抗体是化学分子。人体的自然防御系统产生抗体来抵抗感染。

The U.S. National Institutes of Health notes that some researchers are testing whether antibodies against COVID-19 could be used as a treatment to others who are infected. Others are studying the structure and work of different antibodies to help guide the development of vaccines.

美国国立卫生研究院指出,一些研究人员正在测试新冠肺炎抗体能否用于治疗其他感染者。其他人则在研究不同抗体的结构和作用,以帮助指导疫苗研发。

There are concerns that the novel coronavirus can change in humans and resist the antibodies.

有人担心新冠病毒会在人体内发生变化并抵抗抗体。

Regeneron's REGN-COV2 treatment combines a "genetically-modified" antibody made by the company and a second antibody from recovered COVID-19 patients.

再生元公司的REGN-COV2药物将该公司生产的“转基因”抗体与从新冠肺炎康复患者身上提取的第二种抗体相结合。

The treatment is designed to connect the antibodies to the virus that causes COVID-19 and limit its ability to spread in an infected person. This idea has previously been used to develop drugs to treat other viruses such as HIV, the cause of AIDS.

这种药物旨在将抗体与引发新冠肺炎的病毒联系起来,并限制病毒在感染者中的传播能力。这一想法曾用于研发治疗其他病毒的药物,比如导致艾滋病的艾滋病病毒。

Yancopoulos noted last month that "individual antibodies,no matterhow good, are likely not enough against the devastating virus that causes COVID-19 and the ways it seeks to 'escape' being neutralized."

扬科普洛斯上个月指出,“单个抗体,无论多好,都可能不足以对抗引发新冠肺炎的毁灭性病毒,以及其试图‘逃避’被中和的方式?!?br />
The results of the REGN-COV2 study were published June 15 in Science.

REGN-COV2药物的研究结果于6月15日刊登在《科学》期刊上。

Other drug-makers have begun human trials of their experimental treatments for fighting COVID-19. The companies include Gilead Sciences, Eli Lilly, and AbbVie.

其他制药商已经开始进行新冠肺炎实验性治疗的人体试验。这些公司包括吉利德科学公司、礼来公司以及艾伯维公司。

And that's the Health and Lifestyle report.

以上是健康生活报道。

I'm Anna Matteo.

我是安娜·马迪奥。


分享分享0 收藏收藏0

最新评论

快速回复 返回顶部 返回列表
聚彩彩票